Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCMSCs in Decompensated Alcoholic Cirrhosis
NCT05155657Phase 1Unknown
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of human umbilical cord mesenchymal stem cells in alcoholic cirrhosis (3 arms), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Severity and Incidence of Adverse Events at 24 months. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
alcoholic cirrhosis
Beyond the preview
Go deeper on NCT05155657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155657.